Dexmethylphenidate hydrochloride; serdexmethylphenidate chloride - Generic Drug Details

What are the generic sources for dexmethylphenidate hydrochloride; serdexmethylphenidate chloride and what is the scope of freedom to operate?

Dexmethylphenidate hydrochloride; serdexmethylphenidate chloride is the generic ingredient in one branded drug marketed by Commave Therap and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dexmethylphenidate hydrochloride; serdexmethylphenidate chloride has eighty-seven patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for dexmethylphenidate hydrochloride; serdexmethylphenidate chloride

International Patents:	87
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dexmethylphenidate hydrochloride; serdexmethylphenidate chloride

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for dexmethylphenidate hydrochloride; serdexmethylphenidate chloride

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Anatomical Therapeutic Chemical (ATC) Classes for dexmethylphenidate hydrochloride; serdexmethylphenidate chloride

N06BA	Centrally acting sympathomimetics
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

N06BA	Centrally acting sympathomimetics
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for dexmethylphenidate hydrochloride; serdexmethylphenidate chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-003	May 7, 2021		RX	Yes	Yes
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-003	May 7, 2021		RX	Yes	Yes			Y
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-002	May 7, 2021		RX	Yes	No
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-001	May 7, 2021		RX	Yes	No

International Patents for dexmethylphenidate hydrochloride; serdexmethylphenidate chloride

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2573835	ПРОЛЕКАРСТВА МЕТИЛФЕНИДАТА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ (METHYLPHENIDATE PRODRUGS, METHODS OF THEIR OBTAINING AND APPLICATION)
Israel	297652	הרכבים המכילים קדם-תרופות-מתילפנידט, תהליכים להכנה ושימוש בהם (Compositions comprising methylphenidate-prodrugs, processes of making and using the same)
Finland	3551619
South Korea	20140081761

Market Dynamics and Financial Trajectory for Dexmethylphenidate Hydrochloride and Serdexmethylphenidate Chloride

Last updated: March 5, 2026

What Are Dexmethylphenidate Hydrochloride and Serdexmethylphenidate Chloride?

Dexmethylphenidate hydrochloride (d-MPH) is the pharmacologically active enantiomer of methylphenidate, approved primarily for attention deficit hyperactivity disorder (ADHD). It has been marketed under various brand names since 2010, including Focalin and Focalin XR.

Serdexmethylphenidate chloride is a prodrug of dexmethylphenidate, designed to extend duration and reduce abuse potential. It received FDA approval in 2021 and is marketed as AZSTARYS, combining serdexmethylphenidate with serdexmethylphenidate to enable sustained release.

---

How Does the Market Size Evolve?

Metric	2022 Estimate	2027 Projection	Compound Annual Growth Rate (CAGR)
Global ADHD drug market	$21.4 billion	$31.3 billion	8.0%
Dexmethylphenidate segment	~$1.5 billion	~$2.3 billion	9.2%
Serdexmethylphenidate (AZSTARYS)	New entrant, capturing portion	Increasing	N/A (market emergence)

The ADHD pharmaceutical market registered an 8% CAGR between 2018 and 2022. Dexmethylphenidate compounds account for approximately 7% of this market, primarily in North America.

The launch of serdexmethylphenidate-based products (e.g., AZSTARYS) in 2021 has added a new competitive dynamic, tapping into the extended-release segment and potentially reducing abuse liabilities relative to immediate-release formulations.

---

Who Are the Key Market Players?

Company	Product	Market Share (Estimated)	Key Strategies
Novartis	Focalin, Focalin XR	~30%	Proprietary formulations, expanding indications
Jazz Pharmaceuticals	AZSTARYS (serdexmethylphenidate)	Emerging, capturing niche	Emphasizing abuse-resistant profile, pediatric use
Eli Lilly	Atomoxetine (Strattera)	Larger ADHD segment	Focus on non-stimulant options
Shire (now part of Takeda)	Vyvanse	Largest in long-acting stimulants	Extended duration, abuse deterrence

Most revenue derives from North America, which accounts for over 70% of global ADHD marketed product sales.

---

What Are the Pharmacoeconomic Factors?

• Pricing: Dexmethylphenidate drugs retail between $150–$250 for a 30-day supply. Serdexmethylphenidate formulations currently command premiums (~$300–$350) due to extended-release and abuse-deterrence features.

• Insurance Coverage: Underpins access, with private insurers covering 80–90% of prescriptions in the U.S. and Medicare/Medicaid influencing formulary decisions.

• Patent Landscape: Dexmethylphenidate formulations face patent cliffs from 2023 onward. AZSTARYS has patent protection until 2030, offering a competitive barrier.

• Market Access: Physicians increasingly prefer extended-release formulations to improve adherence, further driving sales of long-acting agents like serdexmethylphenidate.

---

What Are the R&D and Regulatory Trends?

• Pipeline Activity: Multiple companies pursue alternative delivery methods, including transdermal patches and implants. Issues with abuse potential remain a focal point for regulatory agencies.

• Regulatory Approvals: The FDA approved AZSTARYS in 2021. Future approvals are anticipated for generics and biosimilars, which could impact pricing and market share[1].

• Abuse-Deterrent Technologies: Innovations in abuse-resistant formulations are increasingly emphasized, shaping product development strategies.

---

How Will Pricing and Reimbursement Evolve?

Trend	Impact
Increasing utilization of extended-release drugs	Drives higher per-prescription revenue
Greater insurance coverage	Improves market penetration
Price competition from generics	Could pressure branded drug prices
Regulatory emphasis on abuse potential	May favor abuse-deterrent formulations

The trend favors products demonstrating lower abuse potential and improved compliance, favoring serdexmethylphenidate products.

---

What Are the Key Financial Risks?

• Patent Expirations: The loss of exclusivity for dexmethylphenidate brands from 2023 may lead to generic erosion.

• Market Penetration: Slower adoption of new formulations could cap revenue growth.

• Regulatory Hurdles: Stringent abuse-deterrence requirements may delay or restrict product launches.

• Pricing Pressures: Increasing emphasis on cost control could compress profit margins.

---

What Are the Future Market Opportunities?

• Growth in Pediatric Use: Enhanced safety and abuse mitigation drive pediatric prescriptions.

• Global Expansion: Emerging markets show rising ADHD awareness, opening new revenue streams.

• Alternative Delivery Systems: Development of non-invasive, abuse-resistant formats offers differentiation.

• Combination Therapies: Pairing with non-stimulant agents may expand indications and patient compliance.

---

Key Takeaways

• The ADHD drug market is expected to grow at 8% CAGR through 2027, with dexmethylphenidate compounds holding a significant but declining share due to patent expiries and generic competition.
• Serdexmethylphenidate (AZSTARYS) launched in 2021 and is positioned as a sustained-release, abuse-deterrent alternative, capturing niche markets in pediatric and adult ADHD.
• Patent protections extend AZSTARYS' market exclusivity until 2030, providing a revenue window for the company.
• Pricing strategies favor extended-release formulations, though generic competition and reimbursement policies influence margins.
• R&D focuses on abuse resistance, alternative delivery systems, and global expansion.

---

FAQs

1. When will generic versions of dexmethylphenidate become available?

Generic dexmethylphenidate formulations are expected to enter the market post-patent expiration, which begins around 2023 for some brands. This will likely lead to significant price reductions.

2. How does AZSTARYS compare to existing ADHD medications?

AZSTARYS offers a sustained-release profile with abuse deterrence features, targeting patients requiring longer-lasting symptom control. It has a different pharmacokinetic profile compared to immediate-release methylphenidate products.

3. What factors influence the adoption of serdexmethylphenidate products?

Physician familiarity, reimbursement policies, regulatory approval for pediatric use, and the perceived benefit of abuse resistance influence adoption rates.

4. Are there significant regulatory hurdles for new formulations?

Yes. Abuse-deterrent technologies face strict evaluation. Regulators require comprehensive data on safety, efficacy, and abuse potential, which can delay approval.

5. What is the potential impact of global markets on the product portfolio?

Emerging markets present growth opportunities, especially with rising ADHD awareness and unmet needs. Local regulatory environments and pricing pressures will influence success.

---

References

[1] U.S. Food and Drug Administration. (2021). FDA approves AZSTARYS for ADHD.
[2] Grand View Research. (2023). Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size, Share & Trends.
[3] IQVIA. (2022). U.S. Prescription Data for ADHD Medications.
[4] Statista. (2023). Global ADHD Drug Market Revenue Forecasts.
[5] Pharmaceutical Technology. (2022). Abuse-Deterrent Formulations in ADHD Medications.